A new once-daily pill may be just as effective as GLP-1 jabs for treating type 2 diabetes, a trial has found.
Around six million people in the UK are thought to be living with type 2 diabetes, which occurs when the body does not produce enough insulin or cannot use it properly – causing blood sugar levels to become too high.
It is often treated by combining two medicines, metformin and a drug known as an SLGT2 inhibitor, both of which help to lower blood sugar levels.
In some cases, however, patients are offered GLP-1 receptor agonist jabs such as Ozempic, which has
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
